VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | The benefits of NGS in Waldenström’s macroglobulinemia

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, talks on the benefits of next-generation sequencing (NGS) in Waldenström’s macroglobulinemia (WM). NGS has identified MYD88 signaling mutations, which is seen in 95% of patients, as well as CXCR4 mutations present in around 40% of patients, pathing the way for treatment options to target aberrant MYD88 and CXCR4 signaling in WM. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Steven Treon, MD, PhD, has received research funding and consulting fees from Abbvie/Pharmacyclics, Janssen, Beigene, Eli Lilly and X4.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter